Evaluation of Functional Outcomes and Quality of Life Assessments in Patients with Malignant Tumors of the Musculoskeletal System.
- Author:
Sang Hoon LEE
1
;
Dong Joon KIM
;
Joo Han OH
;
Hyuk Soo HAN
;
Han Koo LEE
;
Han Soo KIM
Author Information
1. Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul.
- Publication Type:Original Article
- Keywords:
Malignant bone tumor;
Validity;
Reliability;
Functional evaluation;
Quality of life
- MeSH:
Extremities;
Health Surveys;
Humans;
Knee Joint;
Lower Extremity;
Musculoskeletal System*;
Osteosarcoma;
Outcome Assessment (Health Care);
Quality of Life*;
Reproducibility of Results
- From:The Journal of the Korean Orthopaedic Association
2001;36(2):107-114
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was designed to validate the functional evaluation system after surgery of malignant musculoskeletal tumors by ISOLS (International Symposium On Limb Salvage). MATERIALS AND METHODS: The reliability, content and criterion validities of the ISOLS system were investigated using the Nottingham Health Profile, the Medical Outcome Study 36-item Short-Form Health survey and the EuroQol instrument to measure the quality of life of patients with malignant musculoskeletal tumors. Forty nine patients were evaluated Osteosarcoma around knee joint was most commonly. Prosthetic reconstruction was performed in 55.1%. RESULTS: In content validity analysis, no social and psychological domains was found in ISOLS and the domains for functions of the lower extremities had a strong Cronbach's coefficient (0.88). ISOLS exhibited strong correlation in criterion validity. Convergent validity was good but the discriminative validity was poor. ISOLS has reliability with a strong correlation with other golden standard outcome measures. CONCLUSION: Overall reliability and validity of the ISOLS system appeared to be acceptable. However, this system may need further development of its appropriate domains to evaluate the quality of life in patients with malignant musculoskeletal tumors.
